Cargando…
Treatment of Pediatric Helicobacter pylori Infection
Helicobacter pylori infection can cause gastritis, gastric or duodenal ulcers, mucosa-associated lymphoid tissue lymphoma, gastric cancer, and extra-gastrointestinal manifestations. Ideal treatment should be guided by antibiotic susceptibility testing. However, this is not feasible in many regions,...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219902/ https://www.ncbi.nlm.nih.gov/pubmed/35740162 http://dx.doi.org/10.3390/antibiotics11060757 |
_version_ | 1784732236748161024 |
---|---|
author | Lai, Hung-Hsiang Lai, Ming-Wei |
author_facet | Lai, Hung-Hsiang Lai, Ming-Wei |
author_sort | Lai, Hung-Hsiang |
collection | PubMed |
description | Helicobacter pylori infection can cause gastritis, gastric or duodenal ulcers, mucosa-associated lymphoid tissue lymphoma, gastric cancer, and extra-gastrointestinal manifestations. Ideal treatment should be guided by antibiotic susceptibility testing. However, this is not feasible in many regions, so the treatment generally relies on clinical experience and regional culture sensitivity profiles. We aimed to integrate the treatment of pediatric H. pylori infection through a systematic literature review. Databases including PubMed, Cochrane Library, EMBASE, and Scholar were searched using terms containing (Helicobacter OR Helicobacter pylori OR H. pylori) AND (child OR pediatric) for all relevant manuscripts and guidelines, published from January 2011 to December 2021. The eradication rate for pediatric H. pylori infection was not satisfactory using triple therapy, sequential therapy, concomitant therapy, bismuth-based quadruple therapy, or adjuvant therapy with probiotics as the first-line therapy. Most therapies could not achieve the recommended eradication rate of >90%, which may be attributed to varying regional antibiotic resistance and possible poor children’s compliance. More studies are required to establish a best practice for pediatric H. pylori infection treatment. |
format | Online Article Text |
id | pubmed-9219902 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92199022022-06-24 Treatment of Pediatric Helicobacter pylori Infection Lai, Hung-Hsiang Lai, Ming-Wei Antibiotics (Basel) Review Helicobacter pylori infection can cause gastritis, gastric or duodenal ulcers, mucosa-associated lymphoid tissue lymphoma, gastric cancer, and extra-gastrointestinal manifestations. Ideal treatment should be guided by antibiotic susceptibility testing. However, this is not feasible in many regions, so the treatment generally relies on clinical experience and regional culture sensitivity profiles. We aimed to integrate the treatment of pediatric H. pylori infection through a systematic literature review. Databases including PubMed, Cochrane Library, EMBASE, and Scholar were searched using terms containing (Helicobacter OR Helicobacter pylori OR H. pylori) AND (child OR pediatric) for all relevant manuscripts and guidelines, published from January 2011 to December 2021. The eradication rate for pediatric H. pylori infection was not satisfactory using triple therapy, sequential therapy, concomitant therapy, bismuth-based quadruple therapy, or adjuvant therapy with probiotics as the first-line therapy. Most therapies could not achieve the recommended eradication rate of >90%, which may be attributed to varying regional antibiotic resistance and possible poor children’s compliance. More studies are required to establish a best practice for pediatric H. pylori infection treatment. MDPI 2022-06-01 /pmc/articles/PMC9219902/ /pubmed/35740162 http://dx.doi.org/10.3390/antibiotics11060757 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lai, Hung-Hsiang Lai, Ming-Wei Treatment of Pediatric Helicobacter pylori Infection |
title | Treatment of Pediatric Helicobacter pylori Infection |
title_full | Treatment of Pediatric Helicobacter pylori Infection |
title_fullStr | Treatment of Pediatric Helicobacter pylori Infection |
title_full_unstemmed | Treatment of Pediatric Helicobacter pylori Infection |
title_short | Treatment of Pediatric Helicobacter pylori Infection |
title_sort | treatment of pediatric helicobacter pylori infection |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219902/ https://www.ncbi.nlm.nih.gov/pubmed/35740162 http://dx.doi.org/10.3390/antibiotics11060757 |
work_keys_str_mv | AT laihunghsiang treatmentofpediatrichelicobacterpyloriinfection AT laimingwei treatmentofpediatrichelicobacterpyloriinfection |